Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. 1990

K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
Department of Medicine, Lenox Hill Hospital, New York, NY 10021.

The frequency and pathophysiology of hyponatremia were studied in the acquired immunodeficiency syndrome. Of 71 hospitalized patients surveyed retrospectively, hyponatremia was observed in 37 (52%). Of 48 patients studied prospectively, 27 (56%) were hyponatremic. In 16 hyponatremic patients, volume status; serum and urine osmolalities; renal, adrenal, and thyroid function; and plasma vasopressin levels were assessed. Urine osmolalities were inappropriately elevated (mean, 377 mmol/kg of water) relative to serum osmolalities (mean, 268 mmol/kg of water). Four patients had moderate renal insufficiency. Plasma vasopressin levels were elevated in 15 patients, with the highest levels seen in patients who died (median, 7.08 pmol/L). Hyponatremia of multiple etiologies occurred in a majority of inpatients with the acquired immunodeficiency syndrome, often following the administration of hypotonic fluids, and was associated with a 30% (8/27) short-term mortality.

UI MeSH Term Description Entries
D007010 Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed) Hyponatremias
D008297 Male Males
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin

Related Publications

K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
January 1989, Nephron,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
May 1989, Annals of internal medicine,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
February 1993, The American journal of medicine,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
January 1983, Hormone research,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
January 2014, PloS one,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
June 1984, Presse medicale (Paris, France : 1983),
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
October 1983, Disease-a-month : DM,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
October 1988, Tropical doctor,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
July 1989, The Medical journal of Australia,
K E Vitting, and M H Gardenswartz, and P M Zabetakis, and M L Tapper, and G W Gleim, and M Agrawal, and M F Michelis
January 1987, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
Copied contents to your clipboard!